Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain AgingPRNewsWire · 3 days ago
Genprex to Present at the H.C. Wainwright 28th Annual Global Investment ConferencePRNewsWire · Sep 8, 2026
Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene TherapyPRNewsWire · Aug 18, 2026
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation StudiesPRNewsWire · Aug 3, 2026Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | – | -$9.40 | |
| May 13, 2026 | – | -$14.07 | |
| Mar 30, 2026 | -$286.00 | -$25.30 | Beat |
| Nov 14, 2025 | -$275.00 | -$109.89 | Beat |
| Aug 8, 2025 | -$15.62 | -$187.00 | Miss |
| May 12, 2025 | -$55.88 | -$285.71 | Miss |